VOLUNTARY ANNOUNCEMENT - MELOXICAM INJECTION (III) OBTAINS DRUG REGISTRATION APPROVAL

Hong Kong Exchanges and Clearing Limited and The Stock Excha nge of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoe ver for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this ann ouncement. CSPC PHARMACEUTICAL GROUP LIMITED (Incorporated in Hong Kong with limited liability) (Stock Code: 1093) ʮ ̡ VOLUNTARY ANNOUNCEMENT MELOXICAM INJECTION ( Ⅲ) OBTAINS DRUG REGISTRATION APPROVAL The Board of Directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that Meloxicam Injection ( Ⅲ) (the ‘‘Product ’’) developed by the Group has obtained drug registration appr oval granted by the National Medical Products Administration of the People ’s Republic of China. The approved indication is ‘‘indicated for the treatment of moderate to severe pain in adu lts’’. The Product is the first intravenously administered nanocrystal product approved in China. Meloxicam is a highly selective non-steroidal anti-inflam matory drug. Conventional formulations are generally used for the treatment of chronic pains such as ost eoarthritis and rheumatoid arthritis due to their slow onset and poor analgesic effects. Utilising nove l nanotechnology, the Product reduces the drug particle size to the nanometer range, thereby enabling high-dose, rapid intravenous administration for the treatment of acute moderate to severe postoperative pain. The Product features rapid onset, strong analgesic effect, long-lasting action (24 hours), h igh patient compliance, and an extremely low excipient level, demonstrating a good safety profile. It is expected to become a superior treatment option for the management of acute moderate to severe pain. The approval of the Product further enriches the Group ’s product portfolio in the therapeutic area of analgesic treatment and marks another major breakthrough f or the Group in the field of nanomedicine research and development. By order of the Board CSPC Pharmaceutical Group Limited CAI Dong Chen Chairman Hong Kong, 23 June 2025 As at the date of this announcement, the Board comprises Mr. C AI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chu nlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Steph en and Ms. LI Quan as independent non-executive directors.

The release as fetched from its publisher. irasia.com ↗